Tirzepatide use in adolescents with metabolic dysfunction-associated steatotic liver disease (MASLD): A case series
- Design
- Case series · 2 participants · None outcome
- Match to healthy normal-weight adults aged 55–75
- Different populationINDIRECT: two adolescents, both with obesity and MASLD.
- Could weight loss explain it?
- PossiblyNo weight, liver-fat or glycaemic results are reported for the two patients, so weight and metabolic change cannot be separated from any effect.
- Study tier
- Study tier 4VERY_LOW: a case series of two patients with no comparator.
- Assessment
- Version 2 · Two independent AI reviews agreed · Oct 19, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
This report describes two adolescents with obesity and fatty liver disease (MASLD) treated with tirzepatide. The abstract gives no results for these patients; the weight-loss figures it mentions come from earlier adult studies. With two patients and no comparison group, it cannot show whether the drug helped.
01Findings
What the study reported
- Drugs
- Tirzepatide
- Comparator
- not reported in abstract
- Primary outcome
- not reported in abstract
- Effect
- not reported in abstract
- 95% confidence interval
- Not extracted
- Follow-up
- Not stated
- Adverse events
- not reported in abstract
- Limitations
- Two patients, no comparator, and no results in the abstract.
Who was studied
- Obesity status
- obesity in both patients (entry criterion not stated)
- Diabetes status
- not reported in abstract
- Cvd status
- not reported in abstract
- Ckd status
- not reported in abstract
- Baseline condition
- Obesity and metabolic dysfunction-associated steatotic liver disease (MASLD)
- Sample size
- 2
- Inclusion exclusion
- adolescents with obesity and MASLD
Study quality details
- Study design
- Case series
- Sample size
- 2
- Randomization
- no
- Blinding
- n/a
- Comparator
- not reported in abstract
- Follow up duration
- not stated
- Outcome type
- none
- Replication
- not assessed
- Consistency with other evidence
- not assessed
- Population applicability
- INDIRECT
- Statistical precision
- no CI reported; two patients
- Risk of bias
- not assessed
- Funding conflicts
- unclear
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- not reported in abstract
- Industry funded
- Unclear
- Manufacturer
- not stated in source
- Sponsor role
- not reported in abstract
- Author conflicts
- The authors declare no conflicts of interest.
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
04Source
The source, as retrieved
Abstract
Pediatric obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) prevalence has risen markedly over the past decade. Due to transition delays and workforce shortages, pediatric specialists often manage patients into young adulthood, and thus familiarity with adult pharmacotherapies for MASLD is essential. Currently, Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved for adults with metabolic dysfunction-associated steatohepatitis (MASH) and F2-F3 fibrosis; however, dual and triple agonists are being evaluated. Tirzepatide, a dual agonist that targets gastric inhibitory peptide (GIP) and the GLP-1 receptor, has demonstrated superior weight reduction to Semaglutide (-20.2% vs. -13.7%) with a more favorable gastrointestinal adverse effect profile. Adult literature has demonstrated its effectiveness in MASH resolution, and pediatric data suggest it is safe in younger populations. Currently, there are no pediatric/adolescent studies exploring the use of Tirzepatide in MASLD. We present our experience using Tirzepatide in two adolescent patients with obesity and MASLD.
Where this record came from
| Source | Retrieved | Identifier |
|---|---|---|
| pubmed | Oct 18, 2026 | 42865987 first ingestion |